Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cassava Sciences ( (SAVA) ).
On October 22, 2025, Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors. Ms. Bir, a seasoned biopharmaceutical executive, brings a wealth of experience in leading biotech companies through critical inflection points. Her appointment comes as Cassava prepares to initiate its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026. The company anticipates that her expertise in building shareholder value and forging influential relationships with market stakeholders will be invaluable as they advance their TSC-related epilepsy program.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc. is a biotechnology company based in Austin, Texas, focused on developing novel, investigational treatments for central nervous system disorders, including Tuberous Sclerosis Complex (TSC)-related epilepsy. Their proprietary investigational oral small molecule, simufilam, is believed to modulate the activity of the filamin A protein, which plays a role in neuronal development.
Average Trading Volume: 2,500,439
Technical Sentiment Signal: Sell
Current Market Cap: $213M
For an in-depth examination of SAVA stock, go to TipRanks’ Overview page.